Research Nester has released a report titled “Gaucher Disease Market – Global Demand Analysis & Opportunity Outlook 2026” which delivers detailed overview of the global Gaucher disease market in terms of market segmentation by product type, by infusion mode, by clinical type, by end user and by region.

Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.

The global Gaucher disease market is segmented by clinical type into type I, type II and type III, out of which, type I segment, which held a market share of around 80% in the year 2018, is anticipated to hold the largest market share by the end of 2026 and cross a value of around USD 1500 million by the end of 2026 by growing at a CAGR of around 3% over the forecast period, i.e. 2019-2026. Additionally, the type III segment is estimated to grow with the highest CAGR of around 4% over the forecast period.

The global Gaucher disease market is anticipated to achieve a CAGR of around 3% over the forecast period. Increasing incidences of Gaucher’s disease as well as the increasing focus of the pharmaceutical companies on introducing new products that cater to the treatment of Gaucher disease are some of the factors that are significantly contributing towards the growth of the global Gaucher disease market. Additionally, the market is expected to garner a value of around USD 2000 million by the end of 2026 from a value of around USD 1600 million in the year 2018 and further achieve a Y-o-Y growth rate of around 3% in the year 2026 as compared to the previous year.

Regionally, the global Gaucher disease market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Among these regions, Asia Pacific is expected to expand by observing a growth rate of around 1.30x during the assessment period and is primarily driven by nations such as China, India and Japan, where China held the dominant market share of around 41% in the year 2018 owing to the presence of the world’s largest population in the nation, which also raises the possibility of being infected by the Gaucher’s disease and the raising concern amongst the population to get vaccinated from such disease.

Growing Incidences of Gaucher Disease

In the statistics by the National Organization for Rare Disorders (NORD), the United States alone is estimated to have around 6000 individuals who have Gaucher disease.

The risk of development of the Gaucher disease increases with consanguinity in the family, raising concern amongst people around the globe for the rising incidences of Gaucher disease. Gaucher disease is known to be a common genetic disorder amongst the Ashkenazic Jewish population. The Ashkenazic Jewish population forms about 75% of the world’s total Jewish population. Growing concern for the mutation of gene or transfer of disease to other individuals, along with rising per capita expenditure on healthcare by several nations around the globe and the growing support and funding of the government of nations are some of the factors anticipated to drive the growth of the global Gaucher disease market.

However, concerns regarding high cost associated with the treatment of the disease and stringent norms of the government of several nations for the use of drugs and treatments of the disease are some of the factors anticipated to limit the growth of the global Gaucher disease market.

This report also provides the existing competitive scenario of some of the key players of the global Gaucher disease market, which includes company profiling of Protalix Inc. (TLV: PLX), Pfizer Inc. (NYSE: PFE), Actelion Pharmaceuticals Ltd., Sanofi (EPA: SAN) and Takeda Pharmaceutical Company Limited (TYO: 4502). The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global Gaucher disease market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.